News

Funding will fuel continued research advancement with goal of reducing complications of cystic fibrosis and identifying therapeutic options for those who currently lack them.

Data from Canadian Cystic Fibrosis Registry 2022 Annual Data Report  suggest that today’s babies with cystic fibrosis could live longer than ever before;  fatal disease requires further action to change prognosis. 

The Driven Brands collision group announced its monumental North American milestone of raising over $5 million for cystic fibrosis research, care, and advocacy.

Provinces and territories have begun funding for younger age group following positive recommendation from CADTH. 

Cystic Fibrosis Canada celebrated Giving Tuesday with the launch of its annual holiday fundraising campaign, One Day, Now. 

Cystic Fibrosis Canada calls on jurisdictions to fund the drug immediately for all who can benefit, and eliminate deductibles around access 

Toronto, Ontario – Cystic Fibrosis Canada has awarded $250,000 in seed grants to five researchers to encourage new and innovative research projects in support of the organization’s pledge to go further in fueling targeted, world-class cystic fibrosis (CF) research.  

Last week at CARSTAR’s annual Evolution Conference in Montreal, Quebec, Cystic Fibrosis Canada and the collision and glass service organization celebrated the milestone of 25 years of partnership.

Cystic Fibrosis Canada’s Chief Scientific Officer, Dr. Paul Eckford, recently attended the European CF Society’s annual conference where important advances in research and clinical care were shared.   

Cystic Fibrosis Canada’s Healthcare Advisory Council has published recommendations for the follow-up of pregnancies and newborns of mothers who are receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators, like Trikafta.